$4.83 Billion is the total value of RTW INVESTMENTS, LP's 106 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACHL | Exit | ACHILLES THERAPEUTICS PLCsponsored ads | $0 | – | -12,229 | -100.0% | -0.00% | – |
| BOLT | Exit | BOLT BIOTHERAPEUTICS INC | $0 | – | -126,365 | -100.0% | -0.01% | – |
| MDXG | Exit | MIMEDX GROUP INC | $0 | – | -295,748 | -100.0% | -0.03% | – |
| Exit | SEMA4 HOLDINGS CORP | $0 | – | -400,000 | -100.0% | -0.03% | – | |
| Exit | MINK THERAPEUTICS INC | $0 | – | -416,666 | -100.0% | -0.03% | – | |
| Exit | TANGO THERAPEUTICS INC | $0 | – | -180,819 | -100.0% | -0.03% | – | |
| BMEA | Exit | BIOMEA FUSION INC | $0 | – | -593,846 | -100.0% | -0.06% | – |
| MRUS | Exit | MERUS N V | $0 | – | -196,231 | -100.0% | -0.09% | – |
| VINC | Exit | VINCERX PHARMA INC | $0 | – | -741,236 | -100.0% | -0.11% | – |
| ABUS | Exit | ARBUTUS BIOPHARMA CORP | $0 | – | -2,504,493 | -100.0% | -0.14% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -1,154,380 | -100.0% | -0.15% | – |
| CLSD | Exit | CLEARSIDE BIOMEDICAL INC | $0 | – | -3,806,018 | -100.0% | -0.15% | – |
| NEO | Exit | NEOGENOMICS INC | $0 | – | -311,111 | -100.0% | -0.16% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -666,666 | -100.0% | -0.32% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -346,842 | -100.0% | -0.34% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -5,968,017 | -100.0% | -0.70% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -582,265 | -100.0% | -0.77% | – |
| IDYA | Exit | IDEAYA BIOSCIENCES INC | $0 | – | -2,520,076 | -100.0% | -0.87% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -6,722,624 | -100.0% | -1.64% | – |
| SPY | Exit | SPDR S&P 500 ETF TRtr unit | $0 | – | -889,739 | -100.0% | -6.17% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.